Total Payments
$33,285
2024 Payments
$11,152
Companies
3
Transactions
31
Payment Breakdown by Category
Consulting$26,366 (79.2%)
Research$6,883 (20.7%)
Food & Beverage$37.18 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $26,366 | 23 | 79.2% |
| Unspecified | $6,883 | 7 | 20.7% |
| Food and Beverage | $37.18 | 1 | 0.1% |
Payments by Type
General
$26,403
24 transactions
Research
$6,883
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $18,017 | 4 | $0 (2024) |
| ModernaTX, Inc. | $13,026 | 25 | $0 (2024) |
| Moderna TX, Inc. | $2,243 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,152 | 11 | ViiV Healthcare Company ($7,187) |
| 2023 | $11,571 | 12 | ViiV Healthcare Company ($7,150) |
| 2022 | $1,780 | 2 | ModernaTX, Inc. ($1,780) |
| 2021 | $5,103 | 5 | ModernaTX, Inc. ($2,860) |
| 2019 | $3,680 | 1 | ViiV Healthcare Company ($3,680) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/20/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| 06/20/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 06/20/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 04/09/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $37.18 | General |
| 02/28/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| 02/28/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $390.00 | General |
| 02/28/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 01/11/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $7,150.00 | General |
| 01/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 01/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| 01/03/2024 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 12/01/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| 12/01/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $65.00 | General |
| 10/04/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| 10/04/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $130.00 | General |
| 10/04/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $65.50 | General |
| 09/22/2023 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $7,150.00 | General |
| 07/26/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 07/26/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 06/01/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $260.00 | General |
| 06/01/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $130.00 | General |
| 02/01/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| 02/01/2023 | ModernaTX, Inc. | — | Consulting Fee | Cash or cash equivalent | $195.00 | General |
| 05/04/2022 | ModernaTX, Inc. | — | — | Cash or cash equivalent | $780.00 | Research |
| Study: Phase 1/2, randomized, observer-blind, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010 candidate seasonal influenza vaccine in healthy adults 18 years and older | ||||||
| 04/22/2022 | ModernaTX, Inc. | — | — | Cash or cash equivalent | $1,000.00 | Research |
| Study: Phase 1/2, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines in Healthy Adults | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Lyophilized Zika Vaccine mRNA-1893 in Adults Aged 18-65 Years and Living in Endemic and Non Endemic Flavivi | ModernaTX, Inc. | $1,365 | 1 |
| Phase 1/2, randomized, observer-blind, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010 candidate seasonal influenza vaccine in healthy adults 18 years and older | ModernaTX, Inc. | $1,365 | 2 |
| A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Lyophilized Zika Vaccine mRNA-1893 in Adults Aged 18-65 Years and Living in Endemic and Non Endemic Flavivi | Moderna TX, Inc. | $1,170 | 1 |
| Phase 1/2, randomized, observer-blind, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010 candidate seasonal influenza vaccine in healthy adults 18 years and older | Moderna TX, Inc. | $1,073 | 1 |
| Phase 1/2, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines in Healthy Adults | ModernaTX, Inc. | $1,000 | 1 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults | ModernaTX, Inc. | $910.00 | 1 |
About Dr. Richard Sutton, MD
Dr. Richard Sutton, MD is a Infectious Disease healthcare provider based in West Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578652046.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Sutton, MD has received a total of $33,285 in payments from pharmaceutical and medical device companies, with $11,152 received in 2024. These payments were reported across 31 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($26,366).
Ad
Practice Information
- Specialty Infectious Disease
- Location West Haven, CT
- Active Since 10/12/2006
- Last Updated 01/20/2015
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1578652046
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in West Haven
Dr. Steven Schnittman, M.d, M.D
Infectious Disease — Payments: $377,803
Infectious Disease $377,803
Dr. Kalpana Gupta, Md, MD
Infectious Disease — Payments: $118,878
Infectious Disease $118,878
Dr. Shaili Gupta, Md, MD
Infectious Disease — Payments: $13.77
Infectious Disease $13.77
Dr. Ann Fisher, Md, MD
Infectious Disease
Infectious Disease